Edward van der Horst - Feb 15, 2024 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
CHIEF SCIENTIFIC OFFICER
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Feb 15, 2024
Transactions value $
-$2,246
Form type
4
Date filed
2/16/2024, 06:37 PM
Previous filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Common Stock Tax liability -$2.25K -2.84K -4.83% $0.79 56.1K Feb 15, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +125K $0.00 125K Feb 15, 2024 Common Stock 125K $0.79 Direct F3
transaction SNSE Stock Option (Right to Buy) Award $0 +90.1K $0.00 90.1K Feb 15, 2024 Common Stock 90.1K $0.79 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
F2 Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.
F3 The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.
F4 Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant.